Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.

The funding market, moving in real timeGet StartedBook a Demo
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

Back to SEC Filings
Bylaws AmendmentItem 5.03 · 8-KLOW RiskPositive

Scribe Therapeutics Inc.

Filed: Jul 27, 2026CIK: 000182157847Health Care
View on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Scribe Therapeutics Inc. filed amended and restated Certificate of Incorporation and Bylaws with Delaware on July 27, 2026, effective upon closing of its IPO. This routine corporate governance update reflects the company's transition to public company status and compliance with securities regulations.

Key Takeaways

Company completed its initial public offering on July 27, 2026, with final prospectus dated July 23, 2026

Amended and Restated Certificate of Incorporation and Bylaws were approved by board and stockholders and became effective at IPO closing

2 more takeaways

Filing Overview

Form Type8-K
Filing DateJul 27, 2026
Item5.03
CategoryBylaws Amendment
CIK000182157847
Accession #0001437749-26-000005
Risk LevelLOW
SentimentPositive
Signalinformational
Topics
ipo spac

What This Means

Corporate governance documents have been amended. Review for changes that affect shareholder rights.
View Full Filing on SEC.govBrowse More Filings